# US 11,299,790 B2 · Compositions and methods for identifying secretory antibody-bound microbes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,790 B2
- Document ID: US11299790B2
- Status: Granted
- Kind: B2
- Application number: 16/993,529
- Filed: 2020-08-14
- Published: 2020-11-26
- Granted: 2022-04-12
- Earliest claimed: 2013-03-12
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Richard Flavell; Noah Palm; Marcel de Zoete
- Web page: https://patentgrep.com/patent/US11299790B2

## CPC

- C12Q 1/689: for bacteria
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61P 37/02: Immunomodulators
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- A61K 2035/115: {Probiotics}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

## Claims

### Claim 1

A method of treating an inflammatory disease or disorder associated with a secretory antibody-bound bacteria in the microbiota of a subject in need thereof, the method comprising administering to the subject at least one therapy selected from the group consisting of at least one vaccine and at least one passive immunotherapy, wherein the at least one therapy induces an immune response directed against the secretory antibody-bound bacteria, wherein the secretory antibody-bound bacteria is Clostridium perfringens.

### Claim 2 (depends on 1)

The method of claim 1, wherein the microbiota of the subject is on or near a mucosal surface of the subject selected from the group consisting of the gastrointestinal tract, the respiratory tract, genitourinary tract and mammary gland.

### Claim 3 (depends on 1)

The method of claim 1, wherein the secretory antibody is at least one selected from the group consisting of IgA1, IgA2, and IgM.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one therapy comprises at least one vaccine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one therapy comprises at least one passive immunotherapy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inflammatory disease or disorder is inflammatory bowel disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inflammatory disease or disorder is colitis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

### Claim 9 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the subject at least probiotic to increase the number of at least one type of bacteria under-represented in the microbiota of the subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein the secretory antibody-bound bacteria is Clostridium perfringens and Bacteroides fragilis.